Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
San Diego, US
28 (est)

Mast Therapeutics Locations

San Diego, US

Mast Therapeutics Metrics

Mast Therapeutics Summary

Founding Date


Market capitalization

$18.2 M

Closing share price


Mast Therapeutics Market Value History

Mast Therapeutics News

Mast Therapeutics Company Life